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Abstract
Extracorporeal membrane oxygenation (ECMO) is a technology capable of providing short-term mechanical support to
the heart, lungs or both. Over the last decade, the number of centres offering ECMO has grown rapidly. At the same
time, the indications for its use have also been broadened. In part, this trend has been supported by advances in circuit
design and in cannulation techniques. Despite the widespread adoption of extracorporeal life support techniques, the
use of ECMO remains associated with significant morbidity and mortality. A complication witnessed during ECMO is the
inflammatory response to extracorporeal circulation. This reaction shares similarities with the systemic inflammatory
response syndrome (SIRS) and has been well-documented in relation to cardiopulmonary bypass. The exposure of a
patient’s blood to the non-endothelialised surface of the ECMO circuit results in the widespread activation of the innate
immune system; if unchecked this may result in inflammation and organ injury. Here, we review the pathophysiology
of the inflammatory response to ECMO, highlighting the complex interactions between arms of the innate immune
response, the endothelium and coagulation. An understanding of the processes involved may guide the design of
therapies and strategies aimed at ameliorating inflammation during ECMO. Likewise, an appreciation of the potentially
deleterious inflammatory effects of ECMO may assist those weighing the risks and benefits of therapy.
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Background
Extracorporeal membrane oxygenation (ECMO) is a
technology capable of providing short-term mechanical
support to the heart, lungs or both. Despite having first
been employed clinically in the 1970s [1], the more
widespread use of ECMO in critically ill adult patients is
a recent phenomenon [2]. Over the last decade, the
number of centres offering ECMO has grown rapidly. At
the same time, the indications for ECMO in adults have
expanded beyond acute severe respiratory and cardiac
failure [3] to include extracorporeal cardiopulmonary
resuscitation (ECPR) [4] and as a bridge to lung trans-
plantation [5]. Due to its origins, the use of ECMO is
much better established in neonatal and paediatric
populations [6]. In fact, neonatal ECMO for respiratory
failure accounts for 43% of the Extracorporeal Life
Support Organisation (ELSO) registry, comprising 25
years of records of paediatric and adult patients under-
going ECMO [7].
Survival rates in neonates and children supported with
ECMO, especially in cases of respiratory failure, are gen-
erally high [8]. For adults, it is difficult to quantify the
mortality of patients undergoing ECMO. Several studies
have varied in their reported mortalities based on indica-
tion and modality [8, 9], ranging from 76% in one cohort
undergoing ECMO and dialysis [10] to 37% in a mixed
veno-venous (VV)/veno-arterial (VA) ECMO group [11].
The ELSO registry, between 1989 and 2014, reports
mortalities for respiratory and cardiac ECMO, of 57%
and 41% respectively [7]. In addition, there are a number
of complications that may occur, any of which is capable
of inflicting serious morbidity. These can be broadly
separated into those related to the ECMO device (e.g.,
oxygenator or pump malfunction, circuit clotting, cannula
issues) and physiological complications (e.g., bleeding,
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haemolysis, and infection). In this review, we examine the
pathophysiology of one less well-recognised complication,
the inflammatory response to ECMO.
The inflammatory response to ECMO
The initiation of ECMO is associated with an immediate
and complex inflammatory reaction, similar to that seen
in systemic inflammatory response syndrome (SIRS) [12].
At that moment when the patient’s blood first comes into
contact with the foreign surface of the extracorporeal cir-
cuit, a variety of coagulative and inflammatory cascades
are activated (Fig. 1). Levels of pro-inflammatory cytokines
rise rapidly [13–19], which, in association with activation
of the complement and contact systems [20–25], results
in leukocyte activation [26–28]. This innate immune re-
sponse, if severe, persistent or unchecked by a compensa-
tory anti-inflammatory response (CARS) [29], may lead to
endothelial injury, disrupted microcirculation, and end-
organ dysfunction [30–35]. Despite major improvements
in pump and circuit design, oxygenators and the advent of
heparin-bonded surfaces, the SIRS response to ECMO re-
mains a clinical concern. While a large volume of work
has been directed towards elucidating and targeting the
inflammatory response to cardiopulmonary bypass (CPB)
[36–38], a closely related form of extracorporeal circula-
tion, much less has been devoted to studying the inflam-
matory response to ECMO.
Differences between ECMO and CPB
ECMO and CPB are closely related and share several
similarities. Both techniques generate a biomaterial-
induced inflammatory response in patients. Despite this,
there are important distinctions between ECMO and
CPB (Table 1), of which anyone attempting to infer from
one to the other must be aware.
The most obvious distinction between ECMO and
CPB is in the duration of support provided. CPB is com-
monly employed for only minutes to hours to facilitate a
surgical procedure. Conversely, ECMO, used in patients
with severe organ failure, can be prolonged for weeks to
months. This difference in duration requires a different
approach to anticoagulation. During CPB, loading doses
of unfractionated heparin between 300 and 500 U/kg
may be used [39], versus 40–80 U/kg during ECMO
[40]. Upon the completion of CPB, protamine sulphate
is administered to reverse the effects of heparin, a prac-
tice which is avoided during and at the conclusion of
ECMO. This is an important distinction, given that the
formation of protamine-heparin complexes is known to
exacerbate the inflammatory response (via activation of
the classical and lectin complement pathways) [41, 42].
Hypothermia is mandatory during CPB, but not com-
monly employed during ECMO. Likewise, haemodilu-
tion, which may also be employed during CPB, is not
seen to the same degree during ECMO. Large observa-
tional studies have demonstrated an association between
the lowest haematocrit recorded during CPB and post-
operative mortality [43]. One suggested explanation for
this is that haemodilution leads to increased neutrophil
activation [44].
As part of the surgical nature of conventional CPB,
cardiotomy suctioning, venting of blood and venous res-
ervoirs are incorporated into circuits. This introduces a
blood-air interface. Multiple studies have detected higher
levels of pro-inflammatory cytokines in cardiotomy-
suctioned blood and, in some instances, lower levels of
anti-inflammatory cytokines, such as IL-10 [45–47]. The
absence of an air/blood interface during ECMO may be
a factor in reducing the inflammatory response.
Commonly, perfusion during CPB is non-pulsatile [48].
During VA-ECMO, depending on the residual function of
the native heart, varying degrees of pulsatile flow are gen-
erated in the face of retrograde arterial perfusion by the
ECMO system. This is not the case in VV-ECMO, which
uses an ‘“in series configuration’, relying on the native
heart for systemic perfusion [49]. Evidence from CPB sug-
gests that pulsatile flow during extracorporeal circulation
may act to reduce the inflammatory response [50]. It has
been hypothesised that this may be due to the ability of
pulsatile perfusion to better sustain the functional state of
the microcirculation [51].
Contrary to ECMO, CPB involves inflicting an ischaemia-
reperfusion injury [36]. Clamping of the aorta during
surgery renders the heart, and to a large extent the lungs,
ischaemic. At the completion of surgery, this clamp is re-
moved and both organs undergo a period of reperfusion.
Each phase causes a significant inflammatory reaction.
In some patients this may prove significant, leading
to the onset of lung ischaemia-reperfusion injury or
so-called pump lung [52].
Finally, there are clear patient differences. The major-
ity of patients undergoing CPB will have chronic disease
(often severe), but are unlikely to be acutely unwell at
the time of the procedure. Conversely, those undergoing
ECMO are usually critically ill.
The pathophysiology of inflammation during
ECMO
The inflammatory response caused by ECMO occurs as a
reaction to the exposure of blood to the extracorporeal
circulation. Both systemic and cellular factors initiate and
propagate the SIRS-like cascade. These include several
humoral and cellular systems, most notably the contact,
intrinsic and extrinsic coagulation, and the complement
systems and endothelial cells, leukocytes, platelets and
cytokines. Here we will consider each in turn, although it
should be borne in mind that these systems are largely
interdependent and still not fully understood.
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The interplay between coagulation and
inflammation
The contact system
The contact system is composed of several associated
plasma proteins: factor XII (Hageman factor), factor XI,
high molecular weight kininogen (HMWK) and prekal-
likrein (Fletcher factor). When blood, in which these
proteins are circulating, comes into contact with the
extracorporeal circulation, factor XII is cleaved into two
proteases: factor XIIa and factor XIIf. Factor XIIa con-
verts prekallikrein into active kallikrein and HMWK into
bradykinin (Fig. 1). This is a rapid process, with Factor
XIIa activity in the ECMO circuit reaching maximal
levels within 10 minutes of initiation [53]. In addition to
Fig. 1 The inflammatory response to extracorporeal membrane oxygenation (ECMO). During ECMO, the complement and contact systems are
activated as a result of blood-biomaterial interaction. The alternative complement pathway (AP) is primarily responsible for producing the anaphylatoxins
C3a and C5a and the membrane attack complex (MAC). This occurs as the result of increased hydrolysis of C3 on the biomaterial surface. The contact
system is responsible for producing activated factor XII (FXIIa), which induces the intrinsic coagulation pathway, leading to thrombin formation. Products
produced by each of these systems, promote the production of pro-inflammatory cytokines and have direct effects on leukocytes, platelets and the
vascular endothelium. In particular, neutrophils are activated, leading to increased neutrophilic infiltration of tissue and eventual organ damage
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their role promoting coagulation, kallikrein and bradyki-
nin drive inflammation. Kallikrein production during
ECMO is known to directly activate neutrophils [54].
More recently, neutralisation of factor XIIa using a novel
inhibitory antibody has been shown to reduce inflamma-
tion in ex-vivo and animal models of ECMO [55].
Bradykinin has pleiotropic effects, which include
stimulating the release of nitric oxide, tumour necrosis
factor-alpha (TNF-α) and IL-10 [56]. Little is known
about bradykinin activity during ECMO, although CPB
is associated with dramatically elevated levels [57]. A
major contributory factor in this is that the lungs,
bypassed during CPB, are the major site of bradykinin
inactivation. This is not likely to be a comparable issue
during VV-ECMO, but may play a role in a VA-ECMO
configuration.
Intrinsic and extrinsic coagulation
Contact system activation eventually leads to triggering
of the intrinsic coagulation pathway. Factor XIIa,
formed as a product of contact activation, activates fac-
tor XI to XIa. In the following step, factor XIa converts
factor IX to IXa, which in turn activates factor X. This
is the intrinsic coagulation pathway (Fig. 1). Conversion
of factor X is the first common step in the coagulation
cascade between the intrinsic and extrinsic pathways.
The extrinsic pathway was traditionally felt to play a
lesser role during extracorporeal circulation, due in part
to the requirement for tissue injury and the subsequent
exposure of tissue factor (TF), althoughTF may be present
within extracorporeal circuits, in pro-inflammatory condi-
tions, despite the absence of tissue injury [58]. The ability
of activated complement to induce the expression of TF
by monocytes may be one way in which this effect is
mediated [59, 60]. Alternatively, Szotowski et al. have
described the ability of TNF-α and IL-6 to induce the
endothelial cell expression of soluble TF [61].
By whichever means the common pathway is arrived
at, activated factor X (FXa) converts prothrombin to
thrombin, which then cleaves fibrinogen to fibrin, result-
ing in subsequent clot formation. In addition to its role
in coagulation, thrombin plays a major part in inflamma-
tion. It is known to increase the expression of P-selectin
and E-selectin by endothelial cells, increasing neutrophil
adherence and activation [62, 63]. Thrombin also
induces endothelial cells to produce platelet activating
factor (PAF), another potent activator of neutrophils
[64], and directly influences neutrophils to express pro-
inflammatory cytokines [65]. Attempts have been made
to limit thrombin generation during extracorporeal cir-
culation using biocompatible circuitry. Several coating
materials are utilised in commercially available ECMO
circuits, most commonly heparin and heparin-like com-
pounds. Studies have demonstrated reduced levels of
thrombin when heparin-bonded minimal extracorporeal
circulation systems (MECC) are used, and these are
functionally similar to ECMO [66, 67].
Platelets
In addition to their role in haemostasis, platelets are a
key mediator of inflammation during ECMO [68]. At
the very outset of extracorporeal circulation, activated
platelets begin to adhere to fibrinogen absorbed by the
circuit. The activation of platelets largely occurs in re-
sponse to thrombin generation, although complement
activation [69] and the physical characteristics of the
circuit also play a part. Adherent platelets undergo alter-
ations in their shape and release their granular content
(as do some circulating platelets). Platelet granules
contain a variety of soluble mediators, including chemo-
kines, pro-inflammatory cytokines, proteases, adhesion
factors, growth factors, angiogenic factors and haemo-
static factors [70, 71]. Bound platelets are also capable of
forming leukocyte conjugates, predominantly with mono-
cytes, but also neutrophils [72]. This platelet-leukocyte
interaction induces leukocytes to secrete pro-inflammatory
cytokines and monocytes to express TF [73, 74]. During
ECMO, these processes appear to be time-dependent, with
a progressive increase in activity noted in one study [68].
ECMO and the complement system
The complement system acts at the forefront of the innate
immune response and, as such, is one of the body’s first
host defences to be activated when ECMO is initiated
[23]. An interactive cascade of over 30 complement-
related proteins acts to destroy and remove foreign sub-
stances identified as “non-self”, in addition to substances
released from damaged cells. Complement achieves this
either by direct cell lysis, by producing a trans-membrane
pore known as a membrane attack complex (MAC), or by
modulating leukocytes via opsonisation or the production
Table 1 Key differences between extracorporeal membrane
oxygenation (ECMO) and cardiopulmonary bypass (CPB)
ECMO CPB
Duration Days to weeks Minutes to hours
Anticoagulation Low-dose heparin High-dose heparin
Reversal of
anticoagulation
Not used Protamine administration
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of pro-inflammatory anaphylatoxins [75]. The comple-
ment cascade may be activated by any or all of three path-
ways: the classical pathway (CP), the alternative pathway
(AP), and the lectin pathway (LP).
Across the three pathways, the first common step in
the cascade is the cleavage of C3 to C3a and C3b (Fig. 1).
In the alternative pathway, subsequent steps result in C5
being cleaved to form C5a and C5b. The two resulting
molecules have distinct effects. C5a is a potent pro-
inflammatory mediator (C3a is also an anaphylatoxin,
albeit not as potent) with several abilities in vivo, includ-
ing increasing leukocyte recruitment, increasing vascular
permeability and inciting further inflammatory mediator
release [76]. On the other hand, C5b progresses through
several steps to produce C5b-9 (the MAC). Given its
antibody independence, it is thought that the AP is the
principal means of complement activation during extra-
corporeal circulation (ECC), occurring as a result of
blood contacting the foreign material of the circuit [77].
Although the complement response to CPB has been
well-described [78–81], the role of complement activation
during ECMO is, by contrast, poorly defined. The few avail-
able studies date from the 1990s and were conducted using
the much less advanced pump and circuit technology that
was available to investigators at that time [19, 21–25]. This
is important, as improvements in both circuitry and pump
technology have likely had a beneficial effect on the levels
of complement activation seen during ECMO. Studies on
CPB have shown us that the use of centrifugal pumps, now
ubiquitous in modern ECMO, reduces complement activa-
tion [82, 83]. In addition, the use of contemporary heparin-
bonded circuits has also been shown to reduce complement
activation [84]. Studies have examined complement activa-
tion in ex-vivo models of ECMO [20, 22, 24], neonatal
ECMO [20, 23, 25] and in adult patients [21]. In keeping
with CPB, all of these studies revealed rapid elevations in
the levels of complement factors during ECMO, with peaks
occurring within 1 to 2 hours.
As previously stated, a key differentiator between the
extracorporeal circulation of CPB and ECMO is their
relative duration. This effect has been described by sev-
eral authors. In two adult patients on ECMO for acute
respiratory distress syndrome (ARDS), Vallhonrat et al.,
described rapid elevations in the levels of C3b and ter-
minal complement complex (TCC) (fluid-phase MAC),
which were evident within 15 minutes of commencing
ECMO. These levels peaked by 60 minutes and had
begun to fall by 180 minutes, reaching near-baseline
levels at 2 days. Of note was the failure to demonstrate
any significant elevation in C4d, a classical pathway
marker [21]. In neonates, Graulich et al. detected peaks
of C3a at 1 hour and of C5a and TCC at 2 hours. How-
ever, contrary to what Vallhonrat et al. observed, TCC
levels did not return to baseline [20].
Ex-vivo studies of complement activation in ECMO
have almost universally failed to uncover peak or falling
levels of complement products. Using heparinised fresh
whole human blood in an ex-vivo circuit, Moen et al. re-
corded levels of C3 activation products and TCC con-
tinuing to rise after 72 hours of ECMO [22]; this points
towards the presence of a negative feedback mechanism
in-vivo, which acts to limit inappropriate complement
activation. Bergman et al. employed an ex-vivo model of
ECMO, with a mixture of non-heparinised citrated fresh
human blood and Ringer’s solution, to examine the
influence of complement activation during ECMO on
blood cell rheological properties. Close correlation be-
tween the levels of complement factors, particularly C5a
and TCC, and white cell deformability were noted, lead-
ing the authors to conclude that high levels of comple-
ment activation during ECMO may play a part in the
rheological deterioration of blood cells [24].
ECMO, the endothelium and leukocytes
Endothelial cell activation
Endothelial dysfunction in the critically ill is an import-
ant marker of poor outcome [85, 86]. Even without be-
ing in direct contact with the extracorporeal circuit, the
vascular endothelium plays a crucial role in the inflam-
matory response during ECMO. In a fashion similar to
that of SIRS, the generation of inflammatory mediators
in response to extracorporeal circulation results in the
widespread activation of the endothelium, with a subse-
quent alteration in endothelial cell gene expression
[87]. This occurs in response to a number of cytokines,
complement products and reactive oxygen species
(ROS). Activated endothelial cells in turn secrete pro-
inflammatory cytokines and increase their expression of
adhesion molecules, leading to the increased trans-
migration of leukocytes.
Early activation of the endothelium occurs in re-
sponse to complement products [88]. These factors act
on endothelial cells to induce the upregulation of P-
selectin. The expression of P-selectin on the endothelial
surface in turn spurs the recruitment of activated leu-
kocytes. This process occurs rapidly, as P-selectin exists
pre-stored in the cytoplasm of endothelial cells. How-
ever, complement-mediated endothelial activation is
short-lived, thus, it is an increase in the circulating
levels of pro-inflammatory cytokines that is responsible
for the later activation of the endothelium [87]. TNF-α
and IL-1β are perhaps the most influential cytokines in
this process [36]. Endothelial activation by either mech-
anism results in the recruitment, “rolling”, firm adhe-
sion and trans-migration of activated neutrophils.
Neutrophilic infiltration is thought to be responsible
for the end-organ damage associated with ECMO [15].
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Neutrophils and monocytes
Neutrophils are activated by several mechanisms trig-
gered by ECMO. This response shares certain similar-
ities with the pathogenesis of ARDS [89]. Complement
contributes to the almost instantaneous activation of
neutrophils on the commencement of extracorporeal cir-
culation [90]. Using a simulated model of ECC, Rinder
et al. have described the importance of C5a and TCC in
this process, showing that the addition of a human
monoclonal antibody directed at C5 significantly inhibits
neutrophil activation [91].
Ex-vivo models of ECMO show that the activation of
neutrophils increases dramatically within the first 30 mi-
nutes, peaks within the first few hours, and declines
thereafter. Of note from these studies, is the observation
that leukocytes do not adhere to the circuitry [26, 27].
Once activated, neutrophils degranulate, releasing stores
of cytotoxic enzymes, such as neutrophil elastase, myelo-
peroxidases and lysozymes. In addition, via a “respiratory
burst”, neutrophils are also capable of releasing cytotoxic
ROS. It is via these mechanisms, both within the vascu-
lature and after trans-migration into the tissues that
neutrophils act as the effectors of organ damage during
ECMO [92]. The site of neutrophil activation during
ECMO is likely to be multifocal, although in one experi-
mental model of ECMO the fundamental role of the
oxygenator was described [14]. During CPB, concentra-
tions of neutrophil elastase, IL-8 and neutrophils are
significantly elevated in bronchoalveolar lavage fluid; fur-
thermore, these levels are correlated with the patients’
arterial partial pressure of oxygen (PaO2)/fraction of
inspired oxygen (FiO2) ratios [93].
While no comparable study has been conducted in
adults on ECMO, early studies, performed in neonates
on ECMO, demonstrated an association between neutro-
phil activation and pulmonary deterioration [23, 27].
Increased neutrophil margination into several tissues,
particularly the lungs, has been described during ECMO,
both in animal models and in neonates [14, 15, 30, 94].
Overall, neutrophil numbers increase after the initi-
ation of extracorporeal circulation [95] and neutrophil
function appears to be preserved [25, 28]. This is
despite the reported adverse effects of ECMO on
leukocyte rheology [96].
Monocytes are also activated in response to ECMO [26],
though this appears to occur more slowly than the activa-
tion of neutrophils [36]. When appropriately stimulated,
monocytes may secrete a number of pro-inflammatory
cytokines [97].
ECMO and cytokines
The initiation of ECMO results in the production of a
variety of pro-inflammatory and anti-inflammatory cyto-
kines. These small proteins have a variety of roles in cell
signalling and are important mediators of the innate im-
mune response. There is little evidence to support a single
“master” cytokine in this process. This has implications in
selecting potential therapeutic interventions. While inter-
ventions aimed at single cytokine targets are unlikely to
overcome the redundancy in the system, more broad-
based approaches, such as cell therapy, appear to have sig-
nificant potential. We subsequently describe the most
studied cytokines with respect to ECMO.
TNF-α is produced by a range of cell types in response
to an inflammatory stimulus. TNF-α has pleiotropic effects
on a variety of tissues; but, perhaps most importantly, it is
a potent activator of neutrophils [98]. Furthermore, it in-
duces the expression of adhesion molecules by endothelial
cells, enhancing the margination of neutrophils. TNF-α
can also stimulate macrophage phagocytosis, enhance the
expression of prostaglandins and increase the formation of
thrombin [99]. TNF-α acts as a negative inotrope at the
macrocirculatory level. During ECMO, it is thought that a
large proportion of early TNF-α release originates from
pre-formed stores in mast cells. In a porcine ECMO study,
McIlwain et al. identified gut mucosal mast cells as the key
contributor to early TNF-α release. During the first 2
hours of ECMO, increased plasma TNF-α was not associ-
ated with increased tissue synthesis. This, combined with a
decreased level of TNF-α found in gut mucosa, led the
authors to hypothesise that mast cell degranulation, in re-
sponse to complement activation, is the likely mechanism
by which TNF-α concentrations are elevated [15]. Higher
levels of TNF-α have been associated with non-survival in
neonates undergoing ECMO [23, 27].
Interleukin-6 is a complicated cytokine, with both pro-
and anti-inflammatory actions. Whilst promoting the
acute phase reaction, expansion and activation of T-cells
and the differentiation of B cells, IL-6 may also down-
regulate the expression of other pro-inflammatory cy-
tokines, as well as up-regulate the expression of the
anti-inflammatory cytokines [100]. Studies have re-
ported consistent elevations in IL-6 levels during
ECMO [15, 18, 30, 32, 101]. IL-6 levels in the lungs
have also been shown to rise after VV-ECMO in an ani-
mal model, where they were associated with parenchymal
damage [30]. Interestingly, given that IL-6 has a key role
initiating the acute phase response and its concentration
is thus usually closely coupled to C-reactive protein (CRP)
production, McIlwain et al. failed to demonstrate any link
between the two during porcine ECMO [15]. In a com-
bined study by Risnes et al., involving children and
adults supported with ECMO, levels of IL-6 were in-
versely associated with survival, with a clear divergence
in IL-6 concentrations between survivors and non-
survivors after two days of ECMO support: survivors
effectively normalised their IL-6 levels whilst those who
died maintained a persistent elevation. This was not
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observed to be the case for other cytokines, such as
IL1-β, IL-8 or IL-10 [102].
IL-8 is a potent neutrophil activator and a chemo-
attractant for neutrophils, basophils and T-lymphocytes.
Studies using simulations and animal models and in ne-
onates have demonstrated rapid elevations of IL-8 after
ECMO commences [15, 18, 27]. Alterations in IL-8 con-
centration appear to follow a temporal trend similar to
TNF-α, with increases noted within the first 15 minutes
of ECMO [15, 27].
A number of other cytokines have also been impli-
cated in the inflammatory response to ECMO and extra-
corporeal circulation. Of note is that low levels of the
anti-inflammatory cytokine IL-10 (at the time of ECMO
initiation) have been associated with poor survival [103].
Future directions
In the last decade, ECMO technology has improved dra-
matically. This has facilitated its uptake in an increasing
number of centres for an ever-growing range of indica-
tions. Ongoing research into anticoagulation, servo
control and membrane lung construction will further
improve the safety and efficacy of ECMO [104]. Add-
itional research (pre-clinical and clinical) is required to
assess the impact of ECMO-induced inflammation on
clinically meaningful outcomes. This work will inform
the requirement for novel anti-inflammatory therapies
that could be used during ECMO. In future, when de-
signing strategies to minimise the inflammatory response
to ECMO, several experimental treatments appear to
have potential, in particular, the use of Factor XII inhibi-
tors and mesenchymal stromal cell (MSC) therapy.
Currently, there is substantial interest in targeting fac-
tor XII as a novel means of anticoagulation [105]. The
use of a factor XII inhibitor in this setting is attractive
given the potential to reduce, or eliminate, the risk of
thrombosis without encountering the bleeding risk associ-
ated with current anticoagulants. A beneficial side-effect
would be the inhibition of contact-mediated inflammation
involving the activation of factor XII. A recombinant
human antibody, 3 F7, which inhibits FXIIa, has been suc-
cessfully tested in a rabbit model of VA-ECMO [55]. Any
future work will need to demonstrate the safety and effi-
cacy of factor XII inhibitors in a large animal model of
ECMO, using contemporary clinical ECMO equipment,
before progression to human studies.
MSC therapy is being investigated as a treatment for a
number of acute inflammatory conditions. MSCs are
multipotent adult stem cells found in most tissues of
mesodermal origin, such as bone marrow [106]. MSCs
have attracted attention due to their immunomodulatory
effects. In-vitro MSCs have been shown to influence
both the adaptive and innate immune response to infec-
tion and inflammation; this ability is bi-directional, that
is to say, MSCs may either promote or ameliorate in-
flammation dependent on the contemporary milieu
[107]. MSCs have been studied in a pre-clinical model of
CPB as a means of reducing the harm associated with
ischaemia-reperfusion injury [108]. Here, infusion of
human MSCs significantly reduced the levels of inflam-
matory cytokines within 3 hours. Given their ability to
influence the innate immune response at a range of
points in the cascade and in a manner consistent with
the local environment, MSCs have the potential to be ef-
ficacious in the setting of ECMO-induced inflammation.
Conclusion
The inflammatory response to ECMO is complex and
multi-faceted. It remains unclear whether this excess in-
flammation is all deleterious, or if it has potential benefits
to the host. In summary, it arises principally due to the
contact and complement systems becoming activated as a
result of blood exposure to the extracorporeal circuit. The
combination of a sustained innate immune response and
the pro-inflammatory aspects of coagulation result in
“pan-endothelial” injury, with leukocyte activation and the
production of pro-inflammatory mediators. This ultim-
ately ends in a systemic inflammatory response and end-
organ damage.
Whilst this process shares a number of similarities with
the inflammatory response witnessed during CPB, there
are also a number of important distinctions. Given the
recent increase in the use of ECMO, there is a relative
paucity of data on the inflammatory response that it in-
duces. This is compounded by the fact that many of the
available studies were conducted prior to the introduction
of modern innovations in ECMO technology. Mechanistic
and outcome information from adult patients is absent.
Clearly all patients supported on ECMO experience some
degree of inflammatory response to ECMO, but currently
there is no physiological rationale to explain the extreme
variation seen in the magnitude of the patients’ responses
to that inflammation, nor their clinical course. Whilst it is
undoubtedly difficult to isolate the relative contribution of
specific components of the inflammatory response (pro-
inflammatory and CARS) to outcomes after ECMO,
failure to do so may lead to a missed opportunity for inter-
vention. The first step towards addressing this deficit is to
not only improve our understanding of the basic science
underpinning the inflammatory response induced by
modern ECMO, but to adopt minimal reporting criteria
for the inflammatory response during human ECMO
studies, in a manner similar to that proposed for CPB
[109]. Such studies should be conducted in models that
are relevant, using technology that is in contemporary
clinical use. A more detailed understanding of the under-
lying processes will allow us to better investigate potential
therapies and design future clinical studies.
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